| Description |
Otelixizumab (ChAglyCD3) is an anti-human CD3 monoclonal antibody and can be used for the research of type 1 diabetes[1].
|
| Related Catalog |
|
| Target |
CD3[1]
|
| In Vitro |
Otelixizumab (ChAglyCD3) has a dose-dependent accumulation and a half-life of about 1.5 days[2]. Otelixizumab targets the ε-chain of the CD3 T-lymphocyte surface receptor, which facilitates the activation of the autoreactive T-lymphocytes responsible for beta cell destruction[2].
|
| In Vivo |
Otelixizumab (ChAglyCD3) (100 μg/mouse; i.v.; once) results in durable disease remission dependent on transferable T cell–mediated tolerance in diabetic transgenic mice[1]. Animal Model: BALB/c-huCD3e mice carrying the human CD3e chain[1] Dosage: 100 μg/mouse Administration: Intravenous injection, once Result: Induced secretion of lower amounts of IL-6. Exhibited up-regulation of regulatory T cells.
|
